TMCnet News
Harvard Apparatus Regenerative Technology Appoints James McGorry as New Chief Executive OfficerHarvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a biotechnology company developing bioengineered organs for clinical use, today announced the appointment of James McGorry, MBA, as Chief Executive Officer, effective July 6, 2015. Mr. McGorry has more than 25 years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. He also has been a member of the HART Board of Directors since February 2013. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150625005269/en/ James McGorry, Chief Executive Officer at Harvard Apparatus Regenerative Technology (Photo: Business Wire). "Jim is the ideal person to lead HART at this time," said John F. Kennedy, Chairman of the Board of Directors at HART. "Jim brings his extensive experience developing, leading and growing life science businesses to our company. He spent 12 years in senior management roles at Genzyme, and as a key leader of the Bio Surgery business there Jim led the commercial development and launch of innovative tissue engineered products. He also brings extensive experience in the fields of personalized medicine and medical devices. For the past two years, Jim has provided invaluable insights as a member of our board, and we expect that HART will benefit greatly from his dedicated guidance as CEO." Mr. Kennedy continued, "We also thank Tom McNaughton, our Chief Financial Officer, for the great work he has done as interim CEO. He and Saverio La Francesca, our Chief Medical Officer, have continued to drive forward our progrms and collaborations that are crucial to our success." "I'm eager to work more closely with the entire HART team to make bioengineered organs for the airways and esophagus available to patients," said Mr. McGorry. "HART has the potential to change the way patients are treated with organ implants that the body integrates as its own. I look forward to working with the team and HART's collaborators to make these goals a reality." Mr. McGorry most recently served as Executive Vice President and General Manager, Translational Oncology Solutions for Champions Oncology and previously was Executive Vice President of Commercial Operations at Accellent. During his 12-year tenure at Genzyme, he held leadership positions across several therapeutic areas, including Bio Surgery, Cardiac Surgery, Oncology and Transplant. Mr. McGorry also was President of Clineffect Systems, an electronic medical records company. He began his life sciences career with Baxter Healthcare Corporation, where he spent 11 years in positions of increasing responsibility. Mr. McGorry also served as an officer in the United States Army for six years, including commanding a special operations Green Beret SCUBA detachment. Mr. McGorry has an MBA with a concentration in healthcare from Duke University, Fuqua School of Business, and a B.S. in engineering from the United States Military Academy at West Point where he was the president of his class. HART plans to provide a corporate update on its second quarter financial call in August following a business review by Mr. McGorry and the management team.
About Harvard Apparatus Regenerative Technology
Forward-Looking Statements
View source version on businesswire.com: http://www.businesswire.com/news/home/20150625005269/en/ |